MIAMI, FL -- (MARKET WIRE) -- March 13, 2007 -- DOR BioPharma, Inc. (OTCBB: DORB) (“DOR,” or “The Company”) announced today that it has successfully completed a 1 year interim analysis in the long-term stability program of the key ingredient of RiVax™, a recombinant subunit vaccine against ricin toxin intended to protect against exposure to ricin that might result from purposeful release of toxin in an aerosolized form or as a poisonous contaminant in food or water.
